Last reviewed · How we verify
Deoxycoformycin
Deoxycoformycin is a Small molecule drug developed by Boston Medical Center. It is currently in Phase 1 development for Hairy cell leukemia. Also known as: pentostatin, dCF.
Deoxycoformycin, also known as pentostatin, is a small molecule inhibitor of the enzyme adenosine deaminase. It is used as an anticancer chemotherapeutic drug, primarily in the treatment of various types of lymphoma and leukemia.
-
Baseline phase 1 → approval rate
+9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2033–2036 | — |
| EMA | EU | 2034–2037 | +0.7 yr |
| MHRA | GB | 2034–2037 | +0.7 yr |
| Health Canada | CA | 2034–2038 | +0.9 yr |
| TGA | AU | 2034–2038 | +1.2 yr |
| PMDA | JP | 2034–2038 | +1.5 yr |
| NMPA | CN | 2035–2039 | +2.3 yr |
| MFDS | KR | 2034–2038 | +1.4 yr |
| CDSCO | IN | 2034–2039 | +1.8 yr |
| ANVISA | BR | 2035–2039 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Deoxycoformycin |
|---|---|
| Also known as | pentostatin, dCF |
| Sponsor | Boston Medical Center |
| Target | Adenosine deaminase, Adenosine deaminase |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 1 |
Approved indications
- Hairy cell leukemia
Common side effects
Key clinical trials
- Pilot Trial of Allogeneic Blood or Marrow Transplantation for Primary Immunodeficiencies (PHASE2)
- A Study to Evaluate Axatilimab Versus Best Available Therapy in Participants With Chronic Graft Versus Host Disease After at Least 2 Prior Lines of Systemic Therapy (PHASE3)
- Allogeneic Hematopoietic Cell Transplantation for Disorders of T-cell Proliferation and/or Dysregulation (PHASE2)
- A Blood Stem Cell Transplant for Sickle Cell Disease (PHASE1)
- Trial of Allogeneic Reduced-Intensity, HLA-Haploidentical Allogeneic Hematopoietic Cell Bone Marrow Transplantation Followed by Graft-versus-Host-Disease (GVHD) Prophylaxis With Cyclophosphamide, Bortezomib and Maraviroc for Hematologic Malignancies ... (PHASE1, PHASE2)
- A Reduced-Intensity Conditioning Regimen (Cyclophosphamide, Pentostatin, Anti-thymocyte Globulin) Followed by Haploidentical Hematopoietic Stem Cell Transplant for the Treatment of Patients With Refractory or Recurrent Severe Aplastic Anemia (PHASE1)
- Allogeneic Hematopoietic Cell Transplantation for Peripheral T Cell Lymphoma (PHASE2)
- A Study of Ruxolitinib vs Best Available Therapy (BAT) in Patients With Steroid-refractory Chronic Graft vs. Host Disease (GvHD) After Bone Marrow Transplantation (REACH3) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Deoxycoformycin CI brief — competitive landscape report
- Deoxycoformycin updates RSS · CI watch RSS
- Boston Medical Center portfolio CI
Frequently asked questions about Deoxycoformycin
What is Deoxycoformycin?
What is Deoxycoformycin used for?
Who makes Deoxycoformycin?
Is Deoxycoformycin also known as anything else?
What development phase is Deoxycoformycin in?
What does Deoxycoformycin target?
Related
- Target: All drugs targeting Adenosine deaminase, Adenosine deaminase
- Manufacturer: Boston Medical Center — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Hairy cell leukemia
- Also known as: pentostatin, dCF
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing